Navigation Links
Sinobiopharma Announces Second Quarter 2010 Financial Results
Date:1/19/2010

in sales of KuTai (cisatracurium besylate). Increased marketing efforts and adoption by physicians are driving KuTai sales growth. -- Gross margin increased 182% to $1,720,308 (80% of sales) for the three months that ended November 30, 2009, from $610,752 (63% of sales) for the three months that ended November 30, 2008. The improvement in gross margin was attributable to operating leverage; as volume increased, the unit cost of manufacturing KuTai has decreased. The improvement in gross margin was also attributable to an increase in the price of KuTai, which is distributed through a GSP licensed distributor while Sinobiopharma controls marketing, delivery terms and pricing. -- The operating expenses for the three months ended November 30, 2009 were $596,154, representing a 63% decrease as compared to $1,594,819 for the three months that ended November 30, 2008. The drop was primarily attributable to the decrease in stock-based compensation expenses, and to a lesser degree to a decline in expenses from reverse takeover activities in the three months that ended November 30, 2008. -- Research and development expenses increased $189,396 from $33,015 for the three months ended November 30, 2008 to $222,411 for the three months that ended November 30, 2009. The increase was mainly due to the technology consulting expenses related to the new drug YiTai (perindopril), for which Sinobiopharma scaled up for production in November 2009, and expenditures related to the research and development of other new drugs during the three-month period that ended November 30, 2009. -- Other expenses decreased $10,568 from $61,172 for the three months that ended November 30, 2008 to $50,604 for the three months that ended November 30, 2009. This decrease was due to a lowered balance of the shareholder loan,
'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
2. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
6. Sinobiopharma Secures Rights to Seven Key Patents
7. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
8. Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
9. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
10. Emissary Capital Group Initiates Coverage on Sinobiopharma
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Modeling Complex ... Biological Systems for Type 2 Diabetes, CAMBRIDGE, Mass., ... on identifying molecular mechanisms, networks and,biomarkers to better understand ... Sirtris Pharmaceuticals, Inc. (Nasdaq: SIRT ),a biopharmaceutical company ...
... CHURCH, Va., April 30 Computer Sciences,Corporation (NYSE: ... M. Wah, chief,medical officer and vice president of ... ranked number 10 in Modern Physician and Modern,Healthcare ... Physician,Executives, published in April. Readers from both magazines ...
... XI,AN, China, April 30 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical ... leading,developer and producer of plant extracts and ... and food production, today,announced that it will ... March 31 on Thursday, May 15, 2008, ...
Cached Biology Technology:Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award 2CSC's Dr. Robert M. Wah Makes Top 10 in 50 Most Powerful Physician Executives List 2
(Date:4/17/2014)... peppers. Information about archaeological remains of ancient chili peppers ... of words for chili peppers in ancient dialects helped ... the value of multi-proxy data analysis. Their results are ... presented in a special feature issue of the ... plant and animal domestication edited by Dolores Piperno, staff ...
(Date:4/17/2014)... April 16, 2014. Kessler Foundation has been named ... from the Department of Defense Spinal Cord Injury ... investigator for the randomized, double-blinded, controlled, multi-site clinical ... and muscle strength after spinal cord injury. Dr. ... Engineering Research at Kessler Foundation. Two additional sites ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
Breaking Biology News(10 mins):Chickens to chili peppers 2Chickens to chili peppers 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2New state-of-the-art biotech and nanotech equipment for INRS 2
... have extraordinarily small balance organs, and scientists have long ... School of Medicine in St. Louis has contradicted a ... heads so vigorously that they had to have smaller, ... Working with a Midwestern zoo and a local ...
... be promising candidates for drug development has become easier ... medicinal chemistry group. Dr Jonathan Baell and Dr ... can be used to weed out those molecules likely ... chemical library for compounds that could be useful in ...
... ─ The National Institutes of Health has awarded Albert ... to combat childhood obesity in the Bronx. Working with ... Center for Einstein, a team of researchers will build ... the classroom to encourage physical activity and promote positive ...
Cached Biology News:Rodeo bull goes head-to-head with zoo dolphins in a study of balance 2Rodeo bull goes head-to-head with zoo dolphins in a study of balance 3Compound screening for drug development made simpler 2Einstein-Montefiore research tackles childhood obesity in the Bronx 2Einstein-Montefiore research tackles childhood obesity in the Bronx 3